Puberty Suppressing Hormones
The question
To ask the Secretary of State for Health and Social Care, if he will hold discussions with Kings College London on the potential merits of pausing recruitment to the new Pathway puberty-blocker trial until an independent panel considers the findings of the Cass Review.
Answered by Dr Zubir Ahmed
Children’s healthcare must always be evidence-led. That’s why we are following expert, independent advice from the Cass Review to implement a package of research to find out how the National Health Service can best support children and young people with gender incongruence.
This includes the PATHWAYS trial, a carefully designed clinical trial to assess the relative benefits and harms of puberty-suppressing hormones as a treatment option for children and young people with gender incongruence.
The trial has received independent scientific, ethical, and regulatory approvals as well as a comprehensive review. The study design, including inclusion criteria and safety protocols, has been thoroughly scrutinised to protect young people's wellbeing. The process has included consideration of robust procedures relating to consent and eligibility.
The trial was designed and will be delivered by an independent research team. This was in conjunction with patient and public involvement as well as clinical and legal experts, including those who specialise on medical ethics. The Department has not conducted its own parallel engagement with advocacy organisations on trial development but is represented, alongside patient and parent representatives, on the National Research Oversight Board to which the research team regularly reports.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →